RET and medullary thyroid gland carcinoma: Of note, selpercatinib gained prior approval on 8 May 2020 for the treatment of metastatic RET fusion-positive NSCLC in adults and advanced or metastatic RET mutant medullary thyroid cancer in patients 12 years of age or greater [29].